Hemodialysis Clinical Trial
Official title:
A Prospective, Multicenter, Six-Month Study on the Effectiveness, Safety and Impact on Health Related Quality of Life (HRQoL) and Depression Symptoms of Paricalcitol Administered to Venezuelan Patients With Chronic Kidney Disease (Stage V) Who Are on Hemodialysis
Verified date | November 2014 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | Venezuela : Ministerio del Poder Popular para la Salud |
Study type | Observational |
This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous [IV]) is administered in Venezuelan patients on hemodialysis who are at risk of developing secondary hyperparathyroidism associated with stage V chronic kidney disease.
Status | Terminated |
Enrollment | 105 |
Est. completion date | November 2013 |
Est. primary completion date | November 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female = 18 years old with documented diagnosis of stage V chronic kidney disease, on hemodialysis at study baseline - Subjects who have been previously treated with vitamin D or its metabolites or naïve to paricalcitol - Subjects in whom the use of paricalcitol is clinically indicated and documented by applicable and routine standard of healthcare (i.e. laboratory assessments and clinical evaluations) according to the criteria of the attending physician and in accordance with the approved label of the product in Venezuela - Subjects that provide written informed consent form stating his/her authorization and willingness to participate in the study and allowing the use and discussion of his/her personal and/or health information before entering the study - Female subjects with reproductive potential must use an approved contraceptive method (intrauterine device, birth control pills or barrier device) during and for three (03) months after discontinuation of treatment Exclusion Criteria: - Subjects with severe hyperparathyroidism (parathyroid hormone [PTH] > 3000 pg/mL) - Subjects with hypercalcemia, adjusted according to serum albumin, hyperphosphatemia, or subjects with calcium-phosphorus product (Ca x P) = 70 - Known hypersensitivity and/or toxicity of vitamin D, its metabolites and/or other components of Zemplar® IV (paricalcitol) - Subjects who have participated in clinical trials within 30 days before the start of the study or who are currently enrolled in a clinical trial or under treatment with any investigational product - Subjects who cannot tolerate or cannot take phosphate binders that do not contain calcium and/or aluminum - Subjects who in the opinion of the investigator, for any reason (including medical reasons) are not eligible and/or appropriate for therapy with synthetic analogs of vitamin D and/or unwilling to complete the study visits |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Venezuela | Site Reference ID/Investigator# 96757 | Acarigua | |
Venezuela | Site Reference ID/Investigator# 96766 | Barquisimeto | |
Venezuela | Site Reference ID/Investigator# 96768 | Caracas | |
Venezuela | Site Reference ID/Investigator# 96760 | Maracaibo | |
Venezuela | Site Reference ID/Investigator# 96761 | Maracaibo | |
Venezuela | Site Reference ID/Investigator# 96770 | Miranda | |
Venezuela | Site Reference ID/Investigator# 96763 | Monagas | |
Venezuela | Site Reference ID/Investigator# 96765 | Naguanagua |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) |
Venezuela,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Achieving at Least a 30% Reduction From Baseline in the Levels of Parathyroid Hormone (PTH) at the Final Study Visit | Baseline Week 1 (Study Visit 1) to Week 24 (Final Study Visit) | No | |
Secondary | Percentage of Participants With Hypercalcemia, Hyperphosphatemia and Elevations of Calcium-Phosphate Product (Ca x P) at Baseline, Week 12, and Week 24 | Hypercalcemia was defined as a value of serum calcium (Ca) greater than or equal to 10.3 mg/dL. Hyperphosphatemia was defined as a value of serum phosphorus (P) greater than or equal to 5.5 mg/dL. Elevated Ca×P was defined as as greater or equal to 56.65 mg^2/dL^2, calculated as the result of multiplying the maximum values of calcium (10.3 mg/dL) and phosphorus (5.5 mg/dL). |
Baseline Week 1 (Study Visit 1), Week 12 (Study Visit 3), Week 24 (Final Study Visit) | Yes |
Secondary | Number of Participants Achieving Parathyroid Hormone (PTH) Levels < 300 pg/mL | Participants who achieved PTH Levels < 300 pg/mL between the first and third study visit (Baseline to Week 12) and the third and final study visit (Week 12 to Week 24). | Baseline to Week 12, Week 12 to Week 24 | No |
Secondary | Number of Participants Achieving PTH Level Reductions to < 300 pg/mL or 30% Below Baseline in 12 or 24 Weeks | Number of participants achieving PTH level reductions to < 300 pg/mL or 30% below Baseline in 12 weeks (Baseline to Week 12 or Week 12 to Week 24) or in 24 weeks (Baseline to Week 24). | Baseline Week 1 (Study Visit 1) to Week 24 (Final Study Visit) | No |
Secondary | European Quality of Life 5 Dimensions (EQ-5D) Parameters of Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression At Baseline, Week 12, and Week 24 | The EQ-5D questionnaire is an international, standardized, generic instrument for describing and valuing health status that is divided into 5 parameters that include mobility, self-care, usual activities, pain/discomfort, anxiety/depression and a visual analogue scale (VAS). For each parameter other than the VAS, participants are asked to indicate which of 5 statements (from 'no problem' to 'extreme problem') best describes their health state. | Baseline Week 1 (Study Visit 1), Week 12 (Study Visit 3), Week 24 (Final Study Visit) | No |
Secondary | European Quality of Life 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Scores At Baseline, Week 12, and Week 24 | The EQ-5D questionnaire is an international, standardized, generic instrument for describing and valuing health status that is divided into 5 parameters that include mobility, self-care, usual activities, pain/discomfort, anxiety/depression and a VAS. For the VAS portion, health status is assessed by participants on a vertical, visual analog scale from 0 to 100 where the endpoints are labeled 'worst imaginable health state' (0) and 'best imaginable health state' (100). | Baseline Week 1 (Study Visit 1), Week 12 (Study Visit 3), Week 24 (Final Study Visit) | No |
Secondary | Beck Depression Inventory (BDI) Scores At Baseline and Final Study Visit | BDI is a 21-item questionnaire, participant self-report rating inventory that measures characteristic attitudes and symptoms of depression. The range of scores is 0 to 63, with a higher value representing a worse outcome. | Baseline Week 1 (Study Visit 1), Week 24 (Final Study Visit) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04892745 -
Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
|
||
Not yet recruiting |
NCT04925674 -
Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.
|
Phase 1 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Withdrawn |
NCT02904343 -
Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study
|
N/A | |
Withdrawn |
NCT01855334 -
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
|
Phase 4 | |
Completed |
NCT01700465 -
Estimating and Predicting Hemodynamic Changes During Hemodialysis
|
N/A | |
Recruiting |
NCT01195519 -
The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis
|
N/A | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00527774 -
Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
Completed |
NCT00776750 -
Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06351007 -
Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK)
|
N/A | |
Withdrawn |
NCT03664141 -
Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study)
|
Phase 3 | |
Completed |
NCT03909698 -
Antibiotic Dosing in Patients on Intermittent Hemodialysis
|
||
Recruiting |
NCT03311321 -
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT06098924 -
HD Patients' Depression and Happiness
|
||
Recruiting |
NCT03419923 -
Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage
|
N/A |